Re: Zenith and Newsoara Biopharma Announce Expanded Licensing and Investment.

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KOO-KOO2

Rank: Treasurer [?]

Points: 10765 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith and Newsoara Biopharma Announce Expanded Licensing and Investment.

in response to

Re: Zenith and Newsoara Biopharma Announce Expanded Licensing and Investment.

fouremm

posted on Nov 17, 2021 06:16PM

As you say, ...Zenith's strategy is to enhance multiple drugs. Yes, this is where we're heading with the collaborators paying and paving the way for clinical trials.

Yes, they are selling it on the cheap (i.e the Newsoara Biopharma Co., Ltd. collaboration) but turns into a plus with some success, as others will follow. Resverlogix could easily follow the same path with its multiple indications.

The big question is will Zenith ($0.30US) and RVX ($0.50 CAN) survive the financial hardships they are facing. The best time for new investors to jump on board at these stock prices.